US · Healthcare · Biotechnology
EPS came in at -1.05 against a street estimate of -0.97 — a miss of 8.2%.
Analysts rate Kodiak Sciences Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $121.67.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 31.69% |
| BlackRock Inc | 6.58% |
| T. Rowe Price Associates, Inc. | 5.17% |
| State Street Corp | 3.85% |
| The Goldman Sachs Group Inc | 3.69% |
| Vanguard Capital Management, LLC | 2.87% |
| BRAIDWELL LP | 2.84% |
| Jupiter Topco LLC | 2.43% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 HEADLINE NUMBERS • Kodiak Sciences announced on September 28, 2026 that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tab | 2026-09-28 |
| Quarterly report · Q2 2026 KODIAK SCIENCES INC. – 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Cash and cash equivalents: $125.9 million as of June 30, 2026 (down from $209 | 2026-08-13 |
| Results announced · Q3 2026 KODIAK SCIENCES INC. — Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss Q2 2026: $65.6 million ($1.05 per share) vs. $54.3 million ($1. | 2026-08-13 |
| Shareholder vote results · Q2 2026 KODIAK SCIENCES INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 2, 2026 with 55,026,544 shares voted (88.53% of total shares entitled | 2026-06-04 |
| Quarterly report · Q1 2026 KODIAK SCIENCES INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $169.5 million in cash and cash equivalents as of March 31, 2026 (down | 2026-05-07 |
| Results announced · Q2 2026 KODIAK SCIENCES INC. — Q1 2026 FINANCIAL RESULTS & BUSINESS SUMMARY --- HEADLINE NUMBERS • Net loss Q1 2026: $58.2 million ($0.94 per share basic/d | 2026-05-07 |
| Proxy statement · Q2 2026 KODIAK SCIENCES INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three directors (Charles A. Bancroft II, Bas | 2026-04-22 |
| Annual report FY2025 KODIAK SCIENCES INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal Year: December 31, 2025 • Public Float: $121.6 million (as of Jun | 2026-03-31 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kodiak Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.